ArticleParasites & vectors2026
Targeting mitochondrial bioenergetics: the "Achilles' heel" of Leishmania.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe parasite Leishmania is the causative agent of leishmaniasis and relies on a single "mitochondrion" as its "powerhouse". It also has a compromised antioxidant defense system. Consequently, potential therapeutic strategies include triggering mitochondrial dysfunction along with subversion of host metabolic bioenergetics; however, such information remains poorly defined. The focus of this study was to delineate the impact of antileishmanials amphotericin B (Ampho B) and miltefosine (hexadecylphosphocholine [HePC]) on the metabolic bioenergetics of Leishmania parasites vis-à-vis mammalian macrophages.
methodsIn promastigotes, the redox status was evaluated by flow cytometry; levels of ATP were measured by chemiluminescence; and oxygen consumption rate (OCR), extracellular acidification rate (ECAR), and substrate utilization were assessed by XFp Analyzer. In Leishmania donovani (L. donovani)-infected macrophages, expression of metabolic bioenergetics related regulatory molecules was assessed by droplet digital polymerase chain reaction (ddPCR) and immunoblotting.
resultsIn promastigotes, at their respective 50% and 90% inhibitory concentrations (IC
conclusionsTargeting the "mitochondrion" and metabolic reprogramming are effective leishmanicidal strategies adopted by HePC and Ampho B, with the degree of inhibition by HePC exceeding that of Ampho B. Accordingly, screening for compounds capable of mediating metabolic reprogramming could augment the limited armamentarium of antileishmanials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.